Business · 15/09/1994Updated: 10/18/2026 · 1 min read
FDA Determines Regulatory Review Period for Zemuron Injection
Summary
The Food and Drug Administration has officially confirmed the review period for the patent extension of Zemuron SUPTM Injection, following a submission to the US Patent and Trademark Office, as mandated by law.
Original source language: Federal Register — Health and Human ServicesOpen original release →